ALFRED D. STEINBERG, M.D.; MICHAEL F. SELDIN, M.D., Ph.D.; ELAINE S. JAFFE, M.D.; HOWARD R. SMITH, M.D.; DENNIS M. KLINMAN, M.D., Ph.D.; ARTHUR M. KRIEG, M.D.; JEFFREY COSSMAN, M.D.
Angioimmunoblastic lymphadenopathy with dysproteinemia is a disorder characterized by a sudden onset of constitutional symptoms and lymphadenopathy. Patients often have hypergammaglobulinemia, autoantibodies, rashes, thrombocytopenia, or hemolytic anemia. Diagnosis requires a lymph node biopsy that shows architectural effacement, absence of germinal centers, arborization of postcapillary venules, and a polymorphous infiltrate that includes immunoblasts. Early in the disease, activated T cells in blood and lymph nodes stimulate B cells to proliferate and produce antibody. However, late in the disease, immune suppression may result from increased suppressor function. Clonal rearrangements, which are seen in all patients with regard to either the T-cell receptor beta-chain gene or immunoglobulin genes, have been followed by malignant transformation and frank lymphoma in some patients. Thus, this disorder stands partway between benign lymphoid proliferation and clonal lymphoid transformation. The prognosis of this disorder is poor; 75% of patients die within 2 years or develop a lymphoid malignancy. The rest usually go into a sustained remission. Current treatment with corticosteriod and immunosuppressive agents is unsatisfactory, especially because of late immunosuppression and predisposition to infections.
STEINBERG AD, SELDIN MF, JAFFE ES, et al. Angioimmunoblastic Lymphadenopathy with Dysproteinemia. Ann Intern Med. 1988;108:575–584. doi: https://doi.org/10.7326/0003-4819-108-4-575
Download citation file:
Published: Ann Intern Med. 1988;108(4):575-584.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use